戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ne the resection bed in vivo for microscopic residual cancer.
2  on halting progression in models of minimal residual cancer.
3 ed outcomes, even in patients with extensive residual cancer.
4  to assess the capability of QME to identify residual cancer.
5 state, testis, bladder, kidney, thyroid, and residual cancers.
6 was elevated in 24 of 36 (67%) patients with residual cancer; 201Tl detected tumor sites in 13 of 24
7  were predicted to have residual disease had residual cancer (27 of 28 patients).
8                               Assessment for residual cancer after chemoradiation is still problemati
9                  However, many patients have residual cancer after chemotherapy, which correlates wit
10 L-12 protected against growth of microscopic residual cancer after hepatic resection.
11  imaging, tumor, and VAB variables to detect residual cancer after NST (ypT+ or in situ or ypN+) befo
12 telligent VAB algorithm can reliably exclude residual cancer after NST.
13        Forty-seven consecutive patients with residual cancer after resection of PMNSGCT were retrospe
14 chived tumors of limited sample size such as residual cancer after treatment or metastatic biopsies.
15  and may be responsible for the existence of residual cancer after treatment.
16 e assessment of the presence and location of residual cancer after unsuccessful therapy and helped id
17       However, the molecular patterns of the residual cancers after 3 months of docetaxel treatment w
18                   Of the 12 patients who had residual cancer and false-negative serum Tg levels, 6 ha
19 l margin, and furthermore detected extensive residual cancer at the circumferential margin in a case
20                                              Residual cancer burden (pathological measure of residual
21                                              Residual cancer burden (RCB) 0-1 rate was 28% (inclusive
22 dently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemother
23 djuvant therapy (NAT), characterized by high residual cancer burden (RCB) after treatment, have an in
24                                              Residual cancer burden (RCB) distributions may improve t
25 acteristics, pathologic response, calculated residual cancer burden (RCB) in patients with residual d
26 udies have shown the prognostic value of the residual cancer burden (RCB) index to quantify the exten
27 Pathologic response was quantified using the residual cancer burden (RCB) method.
28 nts were pathologic complete response (pCR), residual cancer burden (RCB) rates, and event-free survi
29 -NAT enhances the prognostic accuracy of the residual cancer burden (RCB) score for disease recurrenc
30 g tumor DNA (ctDNA) and its association with residual cancer burden (RCB) using an ultrasensitive ass
31 method to compare the entire distribution of residual cancer burden (RCB) values between clinical tri
32                                              Residual cancer burden (RCB) was calculated as a continu
33 ompared with association of RFS with PCR and residual cancer burden (RCB), while controlling for age,
34              The secondary endpoints include residual cancer burden (RCB)-0 or RCB-I, objective respo
35                    The primary end point was residual cancer burden (RCB).
36  rate of pathologic response, as assessed by residual cancer burden (RCB).
37 edict pathologic complete response (pCR) and residual cancer burden (RCB).
38 rs of pathologic complete response (pCR) and residual cancer burden (RCB).
39                                      pCR and residual cancer burden 0 + 1 rates were 58% (95% CI, 48%
40 ants (36%) had no residual invasive disease (residual cancer burden 0, or pCR).
41                 Pathologic complete response/residual cancer burden class I occurred in 8 of 167 pati
42 in the test set; all cancers were limited to residual cancer burden I.
43 urvival, pathological complete response, and residual cancer burden in the Nottingham discovery cohor
44 n and cyclophosphamide and surgery to assess residual cancer burden index (RCB).
45                Secondary objectives included residual cancer burden scores (RCB) of 0 or 1 (combined)
46                                              Residual cancer burden should be a secondary end point t
47                The secondary end points were residual cancer burden, EFS, toxicity, and immune biomar
48 cal model-estimated tumor proliferation with residual cancer burden, with Pearson correlation coeffic
49  has been refined by the introduction of the residual cancer burden.
50 tifying by receptor status, Ki-67 index, and residual cancer burden.
51 o distinguish inflammation and fibrosis from residual cancer, but a more than 50% decrease in tumor c
52 sults indicate that in vivo QME can identify residual cancer by directly imaging the surgical cavity,
53                 Tumor deposits, margins, and residual cancer can be imaged through the use of fluores
54 metastasis and in whom complete resection of residual cancer can be performed, organ transplantation
55  tumor-cell-intrinsic pathways that regulate residual cancer cell survival and recurrence, much less
56 tumors frequently arise from a population of residual cancer cells - also referred to as minimal resi
57            In mouse models, between 3 and 30 residual cancer cells and MRD (undetectable with current
58 upon exposure to chemotherapeutic treatment, residual cancer cells and non-transformed cells within t
59  as an alternative adjuvant therapy to clear residual cancer cells and prevent tumor recurrence.
60 g that they must have harbored low levels of residual cancer cells at the end of therapy.
61 lignancy effect, that is, the recognition of residual cancer cells by the T cells of the donor, is a
62 resolution imaging resolved small numbers of residual cancer cells during surgery, allowing thorough
63 glue-based carrier was effective in clearing residual cancer cells following incomplete surgery.
64 ranscriptomic and histological signatures of residual cancer cells from neoadjuvant-treated breast ca
65 partial response (pathPR) rate of 15% (< 10% residual cancer cells in the resected specimen).
66    Surgery guided by ACPPD resulted in fewer residual cancer cells left in the animal after surgery a
67                                              Residual cancer cells persist even after targeted therap
68 tress paradoxically promotes the regrowth of residual cancer cells that survive drug treatment.
69                                              Residual cancer cells that survive drug treatments with
70                                          The residual cancer cells that survive treatment serve as th
71 a and can promote the growth and survival of residual cancer cells to foster tumor recurrence and met
72 peutic strategies are necessary to eradicate residual cancer cells to prevent disease recurrence.
73 ethal MOMP drives the aggressive features of residual cancer cells while templating a host of unique
74 d for novel therapeutics that can target the residual cancer cells whose phenotypes are distinct from
75 esponse (pathologic complete response or <5% residual cancer cells) were evaluated using logistic reg
76 s were as follows: 75% complete response (no residual cancer cells), 56% major response (1% to 49% re
77 cancer cells), 56% major response (1% to 49% residual cancer cells), and 33% minor response (> or = 5
78  5 (33%) had specimens that had less than 5% residual cancer cells, and 2 (13%) had specimens that ha
79  with IA gemcitabine had significantly lower residual cancer cells, higher cellular necrosis and evid
80 fers a potentially powerful new way to clear residual cancer cells, showing how restoring immune surv
81 GVM by transfer of active oncolytic virus to residual cancer cells.
82 se may enhance tumor progression features of residual cancer cells.
83  is an appealing approach to induce death of residual cancer cells.
84 were capable of trafficking to and targeting residual cancer cells.
85 ould be used as an adjuvant therapy to clear residual cancer cells.
86 r cells), and 33% minor response (> or = 50% residual cancer cells; complete v major response, P = .0
87 ed as negative results of the biopsy (ie, no residual cancer) corresponding to a surgical pCR.
88  interrogate the surgical cavity, can detect residual cancer directly in the breast cavity in vivo du
89                                     Although residual cancer following preoperative CMT was more like
90 rectum and are often unable to differentiate residual cancer from treatment scarring.
91  Twenty-four Stage II/III TNBC patients with residual cancer &gt; 1 cm post neoadjuvant anthracycline an
92                         Planar images missed residual cancer in high cervical lymph nodes adjacent to
93                 Both imaging agents detected residual cancer in more than half of the patients in who
94 ay be useful for intraoperative detection of residual cancer in surgical tumor margins.
95 able to accurately identify patients without residual cancer in the breast or axilla.
96 ological complete response (i.e., absence of residual cancer in the breast or lymph nodes at the time
97 tomy increases the likelihood of eliminating residual cancer in the cystectomy specimen and is associ
98  survival was associated with the absence of residual cancer in the cystectomy specimen.
99 re the impact of treatment on downstaging of residual cancer in the experimental arm.
100       Postchemotherapy surgical resection of residual cancer may result in 5-year disease-free surviv
101 mponents of liquid biopsies for diagnosis of residual cancer, monitoring of therapy response, and pro
102                                              Residual cancer often responds poorly to systemic therap
103 e risk is mostly associated with presence of residual cancer on explant.
104 , and to determine feasibility for detecting residual cancer on tumor resection margins, using a gene
105 nse; 1 = isolated tumor cells remaining; 2 = residual cancer outgrown by fibrosis; 3 = extensive resi
106                          Here we report that residual cancer persister cells that survive oncogene-ta
107 stance mechanisms underlying the survival of residual cancer 'persister' cells.
108          Seven (78%) of nine patients had no residual cancer; specimens contained fat necrosis.
109                              (2020) identify residual cancer stem cells (CSCs) as a mechanism of immu
110 is may be an effective strategy to eradicate residual cancer stem cells that are otherwise resistant
111 al ovarian cancer and may be attributable to residual cancer stem cells, or cancer-initiating cells,
112  to delay tumor progression by reprogramming residual cancer stem-like cells.
113 ed for the rapid intraoperative detection of residual cancer tissue during breast-conserving surgery.
114 guish them from the features of recurrent or residual cancer to aid subsequent clinical management.
115                 The longest dimension of the residual cancer was measured at MR imaging and correlate
116 l cancer outgrown by fibrosis; 3 = extensive residual cancer) were assessed from 545 rectal cancer pa
117  characteristic curve of 0.91-0.92 to detect residual cancer (ypT+ or in situ or ypN+) after NST.

 
Page Top